What is XGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XGN?

P/E (TTM) is n/a and 52-week range is $2.59 to $12.23 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XGN?

The company profile lists revenue (TTM) near $71M, net income (TTM) near $-1.89B, EPS (TTM) near $-0.81 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Exagen Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Vista, California, US, 24.2M shares outstanding, ISIN US30068X1037 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Exagen Inc

$XGN

Health Care · Biotechnology

IR Run Scenarios

$8.42

+3.06%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 216 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Employees

218

Website

exagen.com/

IPO

2019-09-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)